CVS Raises View as Covid Shots, Tests Offset Weak Flu Season
(Bloomberg) -- CVS Health Corp. raised its full-year forecast as Covid-19 vaccines and testing helped boost first-quarter results and offset a weak cold and flu season.
The health-care company gave 17 million Covid shots at long-term care facilities and at its pharmacies through April. CVS is now immunizing in about 8,300 locations in 49 states, Chief Executive Officer Karen Lynch said Tuesday on a call with analysts.
With about 9,900 locations nationwide, CVS has administered some 23 million virus tests, including 9 million in the first quarter. Vaccines and testing are already attracting foot traffic, company executives said, and about 9% of new customers who received a test through CVS filled a new prescription with the pharmacy.
But the benefits won't last forever. Demand for shots has already slipped about 30%, CVS Chief Financial Officer Eva Boratto said. That's consistent with a national drop-off in interest, with those most eager already immunized. CVS now expects Covid shots to contribute 2% to overall volume growth, at the low end of the 2% to 3% range it originally expected.
Still, CVS says the pandemic has presented opportunities for the company to connect with new customers.
“Rising to meet the challenge of Covid-19 has advanced the transformation of the health-care industry,” Lynch said. “For CVS Health, the chance to serve our nation at such a critical time has further proven the value of our strategy.”
Forecast, Results
Adjusted net income for 2021 will be $7.56 to $7.68 a share, CVS said in a statement, up from an earlier range of $7.39 to $7.55. Adjusted earnings were $2.04 a share, beating the $1.71 expected by Wall Street analysts. Revenue of $69.1 billion also exceeded analysts' average estimate.
CVS rose as much as 3.9% as of 10:29 a.m. in New York, the most intraday since Dec. 3. Through Monday's close, the stock had gained 14% this year.
The boost from tests and vaccines helped offset some of the challenges facing CVS's retail business. Sales in the front of the store, where drugstore items are sold, slid 11% year-over year. A weak cough, cold and flu season, coupled with the pandemic's contagion precautions, kept some customers out of its stores.
Both CVS's pharmacy-benefits manager Caremark and its health insurer Aetna posted year-over-year increases in revenue. CVS, which acquired Aetna in 2018, is trying to combine its pharmacy and insurance benefits with its drugstores.
Health Hubs, or health-centric stores, are a key piece of that effort. CVS opened about 250 new Health Hubs in the quarter, bringing the total to about 800, Lynch said. CVS expects to have about 1,000 by the end of the year, she said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.